Full Breakdown
Trump Considers Major Cannabis Reclassification
12/17/2025, 5:45:46 AM
Overview of the Proposed Reclassification
President Donald Trump is expected to sign an executive order that would reclassify cannabis from a Schedule I drug to a Schedule III drug under the Controlled Substances Act. This change would formally acknowledge cannabis's medical benefits for the first time at the federal level. Currently, cannabis is classified alongside heroin and LSD, indicating a high potential for abuse and no accepted medical use. Moving it to Schedule III would align it with substances like ketamine and Tylenol with codeine, which are recognized for their medical applications but still carry some risk of dependence.
Implications for the Cannabis Industry
The reclassification is anticipated to ease regulatory hurdles, allowing the Food and Drug Administration (FDA) to conduct research on cannabis for medical purposes. This shift could potentially open the door for broader medical use among seniors, veterans, and others. Additionally, it may enable cannabis businesses to access banking services and reduce their tax burdens, as current IRS regulations prevent businesses dealing with Schedule I substances from deducting standard operating expenses.
Industry experts suggest that the reclassification could lead to significant financial relief for cannabis operators, who currently face effective tax rates as high as 80% due to IRS Code 280E. The anticipated executive order may also include directives for Congress to pass the SAFER Banking Act, which would allow legal cannabis businesses to access major banks and financial institutions.
Political Context and Support
Trump's consideration of this executive order follows a series of meetings with cannabis industry executives and health officials, including Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary. The move aligns with Trump's 2024 campaign promise to "unlock the medical uses of marijuana," reflecting a shift in his administration's stance on cannabis compared to previous Republican leadership.
Polling data indicates substantial public support for cannabis reform, with a Gallup poll showing that 64% of U.S. adults believe marijuana should be legal. Trump's potential reclassification could be seen as an attempt to appeal to younger voters, a demographic where his support has waned.
Criticism and Concerns
Despite the potential benefits, the proposal has faced criticism from various quarters. Senator Ron Wyden (D-Ore.) has accused Trump of attempting to "gaslight" the public into believing he has legalized cannabis, pointing out that reclassification does not equate to decriminalization or expunging the records of individuals imprisoned for minor cannabis offenses. Critics argue that without accompanying measures for clemency or broader legalization, the reclassification may not address the ongoing issues stemming from the War on Drugs.
Additionally, some industry leaders express concern that moving cannabis to Schedule III could expose existing businesses to new federal risks under pharmaceutical regulations. Josh Kesselman, founder of RAW Rolling Papers, warned that this could allow large pharmaceutical companies to dominate the market with synthetic THC products, potentially sidelining smaller operators.
What's Next?
The executive order is expected to be signed soon, but the exact timeline remains uncertain. While the reclassification would not legalize cannabis federally, it represents a significant shift in U.S. drug policy that could pave the way for further reforms. The Drug Enforcement Administration (DEA) will ultimately be responsible for implementing the reclassification, which has been under review since the Biden administration initiated the process in 2024.
In conclusion, Trump's anticipated executive order to reclassify cannabis could have far-reaching implications for the cannabis industry, medical research, and federal drug policy. However, the move is not without its critics, and the broader impacts on legalization and social justice issues remain to be seen.
